Alterations in ROS Activity and Lysosomal pH Account for Distinct Patterns of Macroautophagy in LINCL and JNCL Fibroblasts [PDF]
Neuronal ceroid lipofuscinoses (NCL) are lysosomal storage disorders characterized by the accumulation of lipofuscin within lysosomes. Late infantile (LINCL) and juvenile (JNCL) are their most common forms and are caused by loss-of-function mutations in ...
Carmen Aguado +2 more
exaly +8 more sources
Studies of Atypical JNCL Suggest Overlapping With Other NCL Forms
Pediatric Neurology, 1998In the United States, juvenile neuronal ceroid-lipofuscinosis (JNCL) is the most common form of NCL. This study analyzed 191 cases, diagnosed on the basis of age-at-onset, clinical symptomatology, and pathologic findings. Twenty percent (40/191) of these cases from 24/120 families manifested atypical clinical symptomatology and/or pathologic findings ...
Wojciech Kaczmarski +2 more
exaly +3 more sources
5 Positional Cloning of the JNCL Gene, CLN3
Advances in Genetics, 2001Terry J Lerner
exaly +2 more sources
JNCL Patients Show Marked Brain Volume Alterations on Longitudinal MRI in Adolescence
Journal of Neurology, 2008Juvenile neuronal ceroid lipofuscinosis (JNCL, CLN3) is an inherited lysosomal disease. We used longitudinal MRI, for the first time, to evaluate the rate of brain volume alterations in JNCL. Six patients (mean ages of 12.4 years and 17.3 years) and 12 healthy controls were studied twice with 1.5 T MRI.
Koen Van Leemput, Minna Mannerkoski
exaly +3 more sources
Decreased Striatal Dopamine Transporter Density in JNCL Patients With Parkinsonian Symptoms
Neurology, 2000To explore whether striatal dopamine transporters are involved in juvenile neuronal ceroid lipofuscinosis (JNCL) with extrapyramidal signs.Seventeen patients with JNCL entered the study (mean age, 15 years; age range, 10 to 31 years). For clinical evaluation, the authors used the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS ...
Juha O. Rinne +2 more
exaly +3 more sources
Defective Intracellular Transport of CLN3 Is the Molecular Basis of Batten Disease (JNCL) [PDF]
Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with ...
Irma Järvelä +2 more
exaly +3 more sources
The juvenile type of neuronal ceroid lipofuscinosis (JNCL) is a recessively inherited, progressive neurodegenerative disease. In this study the levels of the antioxidant factors coenzyme Q10 (CoQ10) and vitamin E (alpha-tocopherol) were measured in plasma samples of 29 JNCL patients and compared to 48 healthy controls.
T Westermarck +2 more
exaly +3 more sources
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL): Quantitative Description of Its Clinical Variability
Acta Paediatrica, International Journal of Paediatrics, 1988ABSTRACT. The clinical courses of 17 JNCL patients were analyzed retrospectively with the use of a simple, disease‐specific scoring system. The mean observation period was 14 years (range 8–18 years). Scores of 0 (maximal dysfunction) to 3 (normal function) were assigned to each patient's vision, intellect ...
Alfried Kohlschütter, M Albani
exaly +3 more sources
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), or Batten disease, is a childhood neurodegenerative disease that is characterized clinically by progressive visual loss, seizures, dementia, and motor incoordination. Children affected with this disease tend to develop normally for the first 5 years of life.
David A Pearce +2 more
exaly +3 more sources
Methodology of Clinical Research in Rare Diseases: Development of a Research Program in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) via Creation of a Patient Registry and Collaboration With Patient Advocates [PDF]
Juvenile neuronal ceroid lipofuscinosis (JNCL; Batten disease) is a rare, inherited, fatal lysosomal storage childhood disorder. True for many rare diseases, there are no treatments that impact the course of JNCL. The University of Rochester Batten Center's (URBC) mission is to find treatments to slow, halt, or prevent JNCL.Our initial objective was to
Erika F. Augustine +2 more
exaly +3 more sources

